These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16163374)

  • 1. Functional promoter haplotypes of the human FAS gene are associated with the phenotype of SLE characterized by thrombocytopenia.
    Nolsøe RL; Kelly JA; Pociot F; Moser KL; Kristiansen OP; Mandrup-Poulsen T; Harley JB
    Genes Immun; 2005 Dec; 6(8):699-706. PubMed ID: 16163374
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients.
    Wu J; Metz C; Xu X; Abe R; Gibson AW; Edberg JC; Cooke J; Xie F; Cooper GS; Kimberly RP
    J Immunol; 2003 Jan; 170(1):132-8. PubMed ID: 12496392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The -844C/T polymorphism in the Fas ligand promoter associates with Taiwanese SLE.
    Chen JY; Wang CM; Ma CC; Chow YH; Luo SF
    Genes Immun; 2005 Mar; 6(2):123-8. PubMed ID: 15674374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of FAS and FAS ligand genes polymorphism and risk of systemic lupus erythematosus.
    Moudi B; Salimi S; Farajian Mashhadi F; Sandoughi M; Zakeri Z
    ScientificWorldJournal; 2013; 2013():176741. PubMed ID: 24348139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of apoptosis-related microsatellite polymorphisms on chromosome 1q in Taiwanese systemic lupus erythematosus patients.
    Chen JY; Wang CM; Lu SC; Chou YH; Luo SF
    Clin Exp Immunol; 2006 Feb; 143(2):281-7. PubMed ID: 16412052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction.
    Lai HC; Lin WY; Lin YW; Chang CC; Yu MH; Chen CC; Chu TY
    Gynecol Oncol; 2005 Oct; 99(1):113-8. PubMed ID: 15996722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease.
    Wu J; Wilson J; He J; Xiang L; Schur PH; Mountz JD
    J Clin Invest; 1996 Sep; 98(5):1107-13. PubMed ID: 8787672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Fas/Fas ligand-mediated apoptotic cell death of lymphocytes in vitro by circulating anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
    Suzuki N; Ichino M; Mihara S; Kaneko S; Sakane T
    Arthritis Rheum; 1998 Feb; 41(2):344-53. PubMed ID: 9485093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of polymorphic variants in apoptotic genes and their role in susceptibility and clinical progression to systemic lupus erythematosus.
    Glesse N; Vianna P; Paim LMG; Matte MCC; Aguiar AKK; Palhano PL; Monticielo OA; Brenol CV; Xavier RM; Chies JAB
    Lupus; 2017 Jun; 26(7):746-755. PubMed ID: 27909160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus.
    Kanemitsu S; Ihara K; Saifddin A; Otsuka T; Takeuchi T; Nagayama J; Kuwano M; Hara T
    J Rheumatol; 2002 Jun; 29(6):1183-8. PubMed ID: 12064832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal Fas/FasL and caspase-3-mediated apoptotic signaling pathways of T lymphocyte subset in patients with systemic lupus erythematosus.
    Xue C; Lan-Lan W; Bei C; Jie C; Wei-Hua F
    Cell Immunol; 2006 Feb; 239(2):121-8. PubMed ID: 16808908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between the FAS -670 A/G, -1377 G/A, and FASL -844 T/C polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis.
    Lee YH; Song GG
    Clin Exp Rheumatol; 2016; 34(4):634-40. PubMed ID: 27050822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of molecular mimicry and aberrant autoantigen expression is important for development of anti-Fas ligand autoantibodies in patients with systemic lupus erythematosus.
    Mihara S; Suzuki N; Takeba Y; Soejima K; Yamamoto S
    Clin Exp Immunol; 2002 Aug; 129(2):359-69. PubMed ID: 12165095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome.
    Del-Rey M; Ruiz-Contreras J; Bosque A; Calleja S; Gomez-Rial J; Roldan E; Morales P; Serrano A; Anel A; Paz-Artal E; Allende LM
    Blood; 2006 Aug; 108(4):1306-12. PubMed ID: 16627752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of interleukin-10 promoter haplotypes with disease susceptibility and IL-10 levels in Mexican patients with systemic lupus erythematosus.
    Palafox-Sánchez CA; Oregon-Romero E; Salazar-Camarena DC; Valle YM; Machado-Contreras JR; Cruz A; Orozco-López M; Orozco-Barocio G; Vázquez-Del Mercado M; Muñoz-Valle JF
    Clin Exp Med; 2015 Nov; 15(4):439-46. PubMed ID: 25253090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of a microsatellite in FASL to type II diabetes and of the FAS-670G>A genotype to insulin resistance.
    Nolsøe RL; Hamid YH; Pociot F; Paulsen S; Andersen KM; Borch-Johnsen K; Drivsholm T; Hansen T; Pedersen O; Mandrup-Poulsen T
    Genes Immun; 2006 Jun; 7(4):316-21. PubMed ID: 16691186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of TLR4 (D299G, T399I), TLR9 -1486T>C, TIRAP S180L and TNF-α promoter (-1031, -863, -857) polymorphisms with risk for systemic lupus erythematosus among South Indians.
    Rupasree Y; Naushad SM; Rajasekhar L; Uma A; Kutala VK
    Lupus; 2015 Jan; 24(1):50-7. PubMed ID: 25182168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis.
    Li C; Wu W; Liu J; Qian L; Li A; Yang K; Wei Q; Zhou J; Zhang Z
    Pharmacogenet Genomics; 2006 Apr; 16(4):245-51. PubMed ID: 16538171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.
    Vincent FB; Kandane-Rathnayake R; Koelmeyer R; Harris J; Hoi AY; Mackay F; Morand EF
    Lupus Sci Med; 2020 Jun; 7(1):. PubMed ID: 32546562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer.
    Sun T; Zhou Y; Li H; Han X; Shi Y; Wang L; Miao X; Tan W; Zhao D; Zhang X; Guo Y; Lin D
    J Exp Med; 2005 Oct; 202(7):967-74. PubMed ID: 16186185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.